Medical breakthroughs, surgical innovation, drug development, and health technology from China's top hospitals
June 2, 2026
Haisco Pharmaceutical Group signs landmark $3.054 billion partnership with Eli Lilly, marking one of the largest international deals for a Chinese drugmaker and signaling global recognition of China's innovative drug development capabilities.
Read More →June 1, 2026
After 14 years of research and development, Haisco Pharmaceutical Group's innovative intravenous anesthetic Cipepofol becomes the first Chinese original anesthetic drug approved for the U.S. market, benefiting over 40 million patients worldwide.
Read More →June 1, 2026
At Vision China 2026, researchers from Wenzhou Medical University Eye Hospital presented groundbreaking 7-year follow-up data on H.A.L.T. technology lenses, demonstrating sustained myopia control effectiveness that could transform how millions of Chinese children are protected from progressive nearsightedness.
Read More →May 31, 2026
Chinese researchers have developed DeepRare, the first AI system to consistently outperform human experts in rare disease diagnosis. Published in Nature, the system achieved 78.5% Recall@5 compared to physicians' 65.6%, and when combined with genetic data, improved diagnostic accuracy from 39.9% to 69.1%. For the 300 million people worldwide living with rare diseases, this breakthrough could end the five-year diagnostic odyssey.
Read More →May 30, 2026
Chinese researchers have developed Multi-Glau, a three-tier AI system that brings world-class glaucoma diagnosis to rural clinics. Published in npj Digital Medicine, the system achieved 92.54% accuracy in screening and is already deployed across China's hierarchical healthcare system. For the 21 million Chinese citizens with glaucoma, this AI system represents a fundamental shift in what is possible.
Read More →May 29, 2026
Chinese cardiologists have developed QFR — Quantitative Flow Ratio — a wire-free computational technology that measures coronary artery blockage severity from angiogram images alone. The landmark FAVOR III China trial published in The Lancet proved QFR-guided PCI delivers 35% fewer major adverse events at one year. Now deployed across China's major heart centers including Fuwai Hospital and Xijing Hospital, this homegrown innovation is changing how cardiologists worldwide decide which patients need stents.
Read More →May 29, 2026
A comprehensive guide to full body checkup and executive physical screening in China for international visitors. Complete blood work, CT/MRI imaging, tumor markers, and specialist consultation — all completed in a single morning for $200–$3,000 (vs. $8,000–$20,000 in the US). Covers Shanghai, Beijing, Shenzhen hospital options with pricing tiers, visa-free entry logistics, booking via WeChat, and practical tips for health screening travel.
Read More →May 29, 2026
Shandong University researchers identified OTX2 as the master transcription factor that activates the human embryonic genome — a landmark Nature Genetics paper that is already reshaping IVF protocols at China's largest reproductive medicine centers. Covers the science, hospital translation, AI embryo assessment integration, patient impact, IVF costs in China ($4,100–$8,200 vs $15,000–$30,000 in US), and ethical considerations.
Read More →May 28, 2026
Zhejiang University's Sir Run Run Shaw Hospital has developed the world's first bone glue (bone adhesive) — Gu-02 — a minimally invasive fracture treatment that bonds broken bones within minutes, replacing metal plates and screws. This orthopedic innovation has received dual NMPA Innovative Device and FDA Breakthrough Device designations, making it a landmark breakthrough in bone healing technology and China medical device innovation.
Read More →May 28, 2026
With a 99.6% newborn vaccination rate far exceeding the global average of 85%, China's hepatitis B prevention program has become one of the world's most successful public health initiatives, reducing HBV prevalence in children under five to just 0.30% and preventing millions of future liver cancer deaths.
Read More →May 28, 2026
When an 11-year-old girl who had already endured six intestinal resection surgeries faced a life-threatening ovarian tumor, traditional surgical approaches seemed impossible due to severe abdominal adhesions. The solution came from a domestically developed snake-arm single-port surgical robot that performed the complex procedure through a single small incision.
Read More →July 2, 2025
In 2025, Chinese researchers achieved a world-first: a brain implant that enables paralyzed patients to speak expressively, sing, and control computers with their thoughts. This landmark breakthrough, reported in Nature, positions China at the forefront of neuroprosthetic technology alongside Neuralink.
Read More →September 25, 2024
Chinese scientists at Shanghai Changzheng Hospital achieved a world-first by curing type 1 diabetes using autologous iPSC-derived islet cells. A 25-year-old woman became insulin-independent within 75 days after receiving 1.5 million stem cell-derived islet cells—without any immunosuppressive drugs.
Read More →
